Skip to main content
Swing Capital

Solara Active Pharma Sciences Ltd

NSE: SOLARA BSE: 541540Pharma

Solara Active Pharma Sciences Ltd is engaged in business of manufacturing, production, processing, formulating, sale, import, export, merchandising, distributing, trading of APIs.[1]

₹557
52W: ₹422 — ₹734
PE 0 · Book ₹347 · +61% vs book
Market Cap₹2,013 Cr
Stock P/E—Price to Earnings
ROCE4.91%Return on Capital
ROE0.11%Return on Equity
Div. Yield0%Face Value ₹10

Weaknesses

  • −Company has low interest coverage ratio.
  • −The company has delivered a poor sales growth of -3.27% over past five years.
  • −Company has a low return on equity of -12.0% over last 3 years.
  • −Promoters have pledged 31.6% of their holding.

Shareholding Pattern

Promoters42%
FIIs11.59%
DIIs3.75%
Public42.66%
CategoryJun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Promoters37.27%37.27%37.23%▼0.037.94%▲0.742.01%▲4.142.01%42%▼0.042%
FIIs14%14.25%▲0.314.67%▲0.414.63%▼0.014.25%▼0.413.58%▼0.711.98%▼1.611.59%▼0.4
DIIs2.83%3.37%▲0.53.19%▼0.22.61%▼0.62.62%▲0.02.69%▲0.13.64%▲1.03.75%▲0.1
Public45.89%45.11%▼0.844.92%▼0.244.82%▼0.141.1%▼3.741.71%▲0.642.37%▲0.742.66%▲0.3

Financial Statements

MetricDec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales211.94299.43363.49346.95300.31273.01319.15313.54349387.29
Expenses373.61289.63321.25285.63242.62230.42262.12278.79311.65329.74
Operating Profit-161.679.842.2461.3257.6942.5957.0334.7537.3557.55
OPM %-76.28%3.27%11.62%17.67%19.21%15.6%17.87%11.08%10.7%14.86%
Net Profit-275.33-256.4-12.328.028.1-4.8810.53-10.08-17.429.73
EPS ₹-57.36-53.42-3.422.232.25-1.352.91-2.79-4.822.69

AI Insights

Revenue Trend

Mar 2026 revenue at ₹1,369Cr, up 6.6% YoY. OPM at 14%.

Debt Position

Borrowings at ₹637Cr. Debt-to-equity ratio: 0.53x. Moderate leverage.

Capex Cycle

CWIP at ₹205Cr (17% of fixed assets). Moderate ongoing capital expenditure.

Institutional Flow

DIIs: 3.75% (+2.00pp change). FIIs: 11.59% (-7.12pp change). Promoters hold 42%.

Margin & Efficiency

ROCE improving from 0% (Mar 2018) to 5% (Mar 2026). Working capital days: -22.

Recent Announcements